** U.S.-listed shares of Dutch biotech UniQure NV QURE.Odown 5% premarket to $50 after it secures more equity than targeted

** Co announced pricing ~6.3 mln shares, including 526,316 of prefunded warrants, at $47.50 for $300 mln gross proceeds

** Offering size increased from $200 mln and priced at 9.8% discount to stock's last close

** QURE shares had quadrupled over the past two sessions in an eye-watering rally after co early Weds said its experimental gene therapy significantly slowed Huntington's disease progression in an early-to-mid-stage trial

** Co plans to use net offering proceeds to fund potential commercial launch of AMT-130, and development of its other clinical product candidates, per the offering prospectus

** Leerink Partners, Stifel, Van Lanschot Kempen and Guggenheim Secs are bookrunners

** QURE has ~54.9 mln shares outstanding for about $2.9 bln current market cap through Thurs

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))